Get started
Author

Sara Fritzell

Observed names: Fritzell, Sara, S. Fritzell, Sara V. Fritzell
ORCID: 0000-0003-1079-2614
Observed ORCID: 0000-0003-1079-2614
OpenAlex ID: A5034448965
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
2019 · Anne Månsson Kvarnhammar, Niina Veitonmäki, et al. · Journal for ImmunoTherapy of Cancer · 120
PDF
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
2021 · Itziar Otano, Arantza Azpilikueta, et al. · Nature Communications · 86
PDF
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
2013 · Sara Fritzell, Emma Sandén, et al. · Cancer Immunology Immunotherapy · 47
The effect of locally delivered cisplatin is dependent on an intact immune function in an experimental glioma model
2019 · Julio Enríquez Pérez, Sara Fritzell, et al. · Scientific Reports · 44
PDF
Intratumoral COX‐2 inhibition enhances GM‐CSF immunotherapy against established mouse GL261 brain tumors
2013 · Sofia Eberstål, Emma Sandén, et al. · International Journal of Cancer · 39
PDF
IFNγ in combination with IL-7 enhances immunotherapy in two rat glioma models
2013 · Sara Fritzell, Sofia Eberstål, et al. · Journal of Neuroimmunology · 32
Cure of established GL261 mouse gliomas after combined immunotherapy with GM‐CSF and IFNγ is mediated by both CD8+ and CD4+ T‐cells
2008 · Karin Enell Smith, Sara Fritzell, et al. · International Journal of Cancer · 28
Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors
2012 · Sofia Eberstål, Wiaam Badn, et al. · Cancer Immunology Immunotherapy · 26
The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2022 · Michelle H. Nelson, Sara Fritzell, et al. · Molecular Cancer Therapeutics · 12
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
2023 · Karin Enell Smith, Sara Fritzell, et al. · Cancer Immunology Immunotherapy · 10
PDF
Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8+ T cell memory
2014 · Sofia Eberstål, Sara Fritzell, et al. · Journal of Neuroimmunology · 10
Immunizations With IFNγ Secreting Tumor Cells can Eliminate Fully Established and Invasive Rat Gliomas
2009 · Shorena Janelidze, Daniel Bexell, et al. · Journal of Immunotherapy · 10
Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas
2014 · Salina Ströjby, Sofia Eberstål, et al. · Journal of Neuroimmunology · 9
High Grade Gliomas
2012 · A. Leonard, J. Wolff, et al. · Neuro-Oncology · 9
PDF
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
2024 · Barnabas Nyesiga, Mattias Levin, et al. · mAbs · 8
PDF
Abstract 4077: ATOR-1144 is a tumor-directed CTLA-4 x GITR bispecific antibody that acts by depleting Tregs and activating effector T cells and NK cells
2019 · Sara Fritzell, Mattias Levin, et al. · Cancer Research · 8
851 Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4–1BB x 5T4 ADAPTIR™ bispecific antibody
2020 · Michelle Nelson, Robert Miller, et al. · Journal for ImmunoTherapy of Cancer · 3
Abstract 2380: Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody
2019 · Anna Dahlman, Michelle Nelson, et al. · Cancer Research · 3
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al. · Cancer Immunology Research · 1
PDF
837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
2023 · Ida Uddbäck, Sara Fritzell, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Activation of the CD137 Pathway in T cells by a CD137 × 5T4 bispecific ADAPTIR Molecule Requires Co-engagement of CD137 and 5T4
2018 · Gabriele R Blahnik-Fagan, Robert Bader, et al. · The Journal of Immunology · 1
Data from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S1 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S17 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S15 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Works count: 62
Citation count: 507
H-index: 10
I10-index: 12
Year
Topic
Type